Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial

Journal article

Satti I. et al, (2024), The Lancet Infectious Diseases

Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment.

Journal article

Ma J. et al, (2024), Proceedings of the National Academy of Sciences of the United States of America, 121

Revaccination with BCG: does it work?

Journal article

McShane H., (2024), The Lancet. Infectious diseases

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.

Journal article

Wajja A. et al, (2024), The Lancet. Infectious diseases

Exploring the ethics of tuberculosis human challenge models.

Journal article

Rohrig A. et al, (2023), Journal of medical ethics

Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.

Journal article

Wajja A. et al, (2023), The Lancet. Infectious diseases

Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2.

Journal article

Higham HE. et al, (2023), British journal of clinical pharmacology

Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2

Preprint

Higham H. et al, (2023)

Improving TB vaccine trial efficiency: A tough nut to crack.

Journal article

Mcshane H., (2023), The Journal of infectious diseases

A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge.

Journal article

Stylianou E. et al, (2023), Frontiers in immunology, 14

BCG: Past, Present and Future Direction

Chapter

Morrison H. and McShane H., (2023), Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis, 171 - 195

Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges.

Journal article

Morrison H. et al, (2023), Frontiers in immunology, 14

Healthy volunteer symptom profile following research bronchoscopy

Conference paper

Morrison H. et al, (2023), EUROPEAN RESPIRATORY JOURNAL, 62

Practical considerations for a TB controlled human infection model (TB-CHIM); the case for TB-CHIM in Africa, a systematic review of the literature and report of 2 workshop discussions in UK and Malawi.

Journal article

Gordon SB. et al, (2023), Wellcome Open Res, 8

The VALIDATE Network: Accelerating Vaccine Development for Tuberculosis, Leishmaniasis, Melioidosis and Leprosy

Chapter

Vermaak S. et al, (2023), Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis, 11 - 25

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants

Journal article

Satti I. et al, (2022), Nature Communications, 13

Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.

Journal article

Wilkie M. et al, (2022), Scientific reports, 12

Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?

Journal article

Dockrell HM. and McShane H., (2022), EBioMedicine, 79

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.

Journal article

Killingley B. et al, (2022), Nat Med

Challenges in Developing a Controlled Human Tuberculosis Challenge Model.

Journal article

Jackson S. and McShane H., (2022), Curr Top Microbiol Immunol

Load More